These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29999231)

  • 21. Barriers to Health Care Providers' Provision of Long-Acting Reversible Contraception to Adolescent and Nulliparous Young Women.
    Hopkins B
    Nurs Womens Health; 2017; 21(2):122-128. PubMed ID: 28388997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delivery of progestins via the subdermal versus the intrauterine route: comparison of the pharmacology and clinical outcomes.
    Goldstuck ND; Le HP
    Expert Opin Drug Deliv; 2018 Jul; 15(7):717-727. PubMed ID: 29979891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postpartum contraception: initiation and effectiveness in a large universal healthcare system.
    Brunson MR; Klein DA; Olsen CH; Weir LF; Roberts TA
    Am J Obstet Gynecol; 2017 Jul; 217(1):55.e1-55.e9. PubMed ID: 28257962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of progestin-only long-acting contraception on metabolic markers in obese women.
    Bender NM; Segall-Gutierrez P; Najera SO; Stanczyk FZ; Montoro M; Mishell DR
    Contraception; 2013 Sep; 88(3):418-25. PubMed ID: 23410714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long acting reversible contraception in postpartum adolescents: early initiation of etonogestrel implant is superior to IUDs in the outpatient setting.
    Tocce K; Sheeder J; Python J; Teal SB
    J Pediatr Adolesc Gynecol; 2012 Feb; 25(1):59-63. PubMed ID: 22051792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishing and Conducting a Regional, Hands-on Long-Acting Reversible Contraception Training Center in Primary Care.
    Rubin SE; Maldonado L; Fox K; Rosenberg R; Wall J; Prine L
    Womens Health Issues; 2018; 28(5):375-378. PubMed ID: 29891213
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-acting reversible contraception: a review in special populations.
    Prescott GM; Matthews CM
    Pharmacotherapy; 2014 Jan; 34(1):46-59. PubMed ID: 24130075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Association between Immediate Postpartum Etonogestrel Implants and Positive Postpartum Depression Screens in Adolescents and Young Adults.
    Drake E; Grush K; Sheeder J; Tocce K
    J Pediatr Adolesc Gynecol; 2020 Oct; 33(5):550-554. PubMed ID: 32535218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementing Immediate Postpartum Long-Acting Reversible Contraception Programs.
    McHugh KW; Tucker Edmonds B; Ferries-Rowe E; Haas DM
    Obstet Gynecol; 2017 Jun; 129(6):1136-1137. PubMed ID: 28538477
    [No Abstract]   [Full Text] [Related]  

  • 30. In response to: Current barriers and potential strategies to increase the use of long-acting reversible contraception to reduce the rate of unintended pregnancies in Australia: An expert roundtable discussion.
    Turner JV
    Aust N Z J Obstet Gynaecol; 2017 Dec; 57(6):E15-E16. PubMed ID: 29210050
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-acting reversible contraception in adolescents: a systematic review and meta-analysis.
    Diedrich JT; Klein DA; Peipert JF
    Am J Obstet Gynecol; 2017 Apr; 216(4):364.e1-364.e12. PubMed ID: 28038902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary clinical assessment of a task-shifting device for subcutaneous contraceptive implants.
    Bell C; Mohedas I; Soyars C; Sienko KH
    Int J Gynaecol Obstet; 2021 Oct; 155(1):159-161. PubMed ID: 34143452
    [No Abstract]   [Full Text] [Related]  

  • 33. Temporal Trends in the Uptake and Continuation of the Etonogestrel Implant in a Large Private Practice Setting.
    Howard DL; Ford A; Ceballos S; Volker KW
    J Womens Health (Larchmt); 2018 Feb; 27(2):191-195. PubMed ID: 28976797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-acting reversible contraception by effervescent microneedle patch.
    Li W; Tang J; Terry RN; Li S; Brunie A; Callahan RL; Noel RK; Rodríguez CA; Schwendeman SP; Prausnitz MR
    Sci Adv; 2019 Nov; 5(11):eaaw8145. PubMed ID: 31723599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LARCs as first-line contraception - What can general practitioners advise young women?
    Temple-Smith M; Sanci L
    Aust Fam Physician; 2017 Oct; 46(10):710-715. PubMed ID: 29036768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of a long-acting reversible contraceptive (Implanon) relative to oral contraception in a community setting.
    Lipetz C; Phillips CJ; Fleming CF
    Contraception; 2009 Apr; 79(4):304-9. PubMed ID: 19272500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatricians' Attitudes and Beliefs about Long-Acting Reversible Contraceptives Influence Counseling.
    Berlan ED; Pritt NM; Norris AH
    J Pediatr Adolesc Gynecol; 2017 Feb; 30(1):47-52. PubMed ID: 27639750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent progress in advanced biomaterials for long-acting reversible contraception.
    Yan M; Zhang Y; Wu Z; Li Y; Dou K; Wang B; Wang Y; Zhou Q
    J Nanobiotechnology; 2022 Mar; 20(1):138. PubMed ID: 35300702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in the Use of Long-Acting Reversible Contraceptive Methods Among U.S. Nulliparous Women: Results from the 2006-2010, 2011-2013, and 2013-2015 National Survey of Family Growth.
    Ihongbe TO; Masho SW
    J Womens Health (Larchmt); 2018 Mar; 27(3):245-252. PubMed ID: 29148890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.